COMPARISON
Difelikefalin vs Etelcalcetide
5 attributes held for at least one of the two. 4 differ. Each value carries the register it came from and the date that register was read.
Answer
Difelikefalin is authorised or registered in 7 and Etelcalcetide in 7 of the 10 registers read. Difelikefalin: highest phase Phase 3 (1 phase 3 trial, 0 with posted results). Etelcalcetide: highest phase Phase 3 (1 phase 3 trial, 0 with posted results). 0 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Difelikefalin | Etelcalcetide | |
|---|---|---|
| Registered trials differs | 25 clinicaltrials.gov · 2026-10-03 | 24 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: Korsuva openfda · 2026-10-03T17:23:44.062Z | FDA-approved: PARSABIV openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Authorised ema · 2026-10-03 | Authorised ema · 2026-10-03 |
| EU authorised on differs | 2022-04-25 ema · 2026-10-03 | 2016-11-11 ema · 2026-10-03 |
| ATC code differs | V03AX ema · 2026-10-03 | H05BX04 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Difelikefalin | placebo | Etelcalcetide | placebo |
|---|---|---|---|---|
| Hypotension | 13.8% | 9.5% | 5.7% | 6.7% |
| Muscle spasms | 12.5% | 10.7% | 10.0% | 7.8% |
| Diarrhoea | 5.6% | 3.7% | 10.6% | 9.3% |
| Hyperkalaemia | 17.7% | 17.3% | - | - |
| Dialysis hypotension | 13.8% | 10.3% | - | - |
| Upper respiratory tract infection | 9.5% | 10.3% | - | - |
| Dizziness | 9.5% | 5.8% | - | - |
| Constipation | 5.6% | 2.1% | - | - |
| Palpitations | 5.2% | 4.9% | - | - |
| Hypocalcaemia | 4.3% | 1.6% | - | - |
| Blood calcium decreased | - | - | 46.6% | 30.3% |
| Nausea | - | - | 9.1% | 8.1% |
| Vomiting | - | - | 8.9% | 7.3% |
| Headache | - | - | 6.4% | 6.1% |
| Arteriovenous fistula site complication | - | - | 6.1% | 5.4% |
| Pain in extremity | - | - | 6.0% | 4.3% |
| Cough | - | - | 5.7% | 5.6% |
Trial register Difelikefalin: 1 placebo-controlled trials; Etelcalcetide: 4. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Difelikefalin side effects · Etelcalcetide side effects
LEGAL STATUS
Approval in each country read
| Country | Difelikefalin | Etelcalcetide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Not on the register | Regulator Health Canada |
| Australia | Registered | Status unknown | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Not on the register | Not on the register | Regulator ANVISA |
| Serbia | Not on the register | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Not on the register | Ruhsatli | Regulator TITCK |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.